Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 854 matching trials from the live ClinicalTrials.gov search.
Conditions
Endometrial Hyperplasia, Endometrial Cancer, Postmenopausal Bleeding, Vaginal Bleeding
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 120 Years · Female only
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Hillsboro, Oregon
Active, not recruiting Not applicable Interventional

Activity and Cancer Survivorship Exercise Pilot

NCT07283029
Conditions
Endometrial Cancer
Interventions
Functional fitness following home-based comprehensive exercise program
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Boston, Massachusetts • Charlestown, Massachusetts • Newton, Massachusetts + 2 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

ICG to Assess Ovarian Perfusion

NCT03927651
Conditions
Fibroid Uterus, Endometriosis, Uterus Myoma, Uterine Fibroid, Uterine Adenomyosis, Endometrial Cyst, Uterine Cyst
Interventions
ICG
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Endometrial Cancer
Interventions
OK-1 & Paclitaxel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Not applicable Interventional Results available

High Intensity Interval Training in Endometrial Cancer

NCT04025229
Conditions
Endometrial Cancer
Interventions
HIIT exercise
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
Interventions
thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Endometrial Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Breast Cancer, Endometrial Cancer
Interventions
Genistein, Placebo
Dietary Supplement
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Houston, Texas
Active, not recruiting Phase 1 Interventional

TH1902 in Patients With Advanced Solid Tumors

NCT04706962
Conditions
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Interventions
TH1902
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Detroit, Michigan • Grand Rapids, Michigan • Gettysburg, Pennsylvania + 2 more
Conditions
Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms, Solid Carcinoma, Pancreatic Cancer
Interventions
DM002
Drug
Lead sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • Huntersville, North Carolina • Oklahoma City, Oklahoma + 1 more
Conditions
Gynecologic Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Gilbert, Arizona • Houston, Texas
Conditions
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
MK-3475, INCB024360
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Conditions
Solid Tumors
Interventions
Bemarituzumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 7 more
Conditions
Prostate, Brain, Breast, Lung, Endometrial
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 90 Years
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
Interventions
Lenvatinib Mesylate, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
Floor Backes
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Ovary Cancer, Endometrial Cancer
Interventions
Educational videos, Survey
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions
Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Conditions
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
Interventions
KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6, FOLFIRI, Pemetrexed, Carboplatin
Drug
Lead sponsor
Kestrel Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cancer
Interventions
recombinant adenovirus-hIFN-beta
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Endometrial Cancer, Uterine Cancer, Cervical Cancer
Interventions
PINPOINT
Device
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Jose, California • Fort Myers, Florida • New York, New York + 2 more